1 | De Vries et al19 | (1) Identify life domains relevant to patients with IPF | SGRQ* |
| | (2) Determine whether the SGRQ or WHOQOL-100 was preferred for assessing these aspects | WHOQOL-100* |
| | | |
2 | Martinez et al21 | (1) Examine associations between HRQL and measures of dyspnoea and pulmonary function | SF-36† |
| | (2) Compare HRQL in patients with IPF and healthy people | |
| | | |
3 | De Vries et al20 | (1) Assess QOL in IPF patients | WHOQOL-100* |
| | (2) Identify clinical parameters related to QOL |
| | (3) Determine clinical predictors of QOL scores | |
| | | |
4 | Martinez et al22 | Examine association between HRQL and multiple dyspnoea scales | SF-36† |
| | | |
5 | Nishiyama et al16 | (1) Identify the association between clinical markers of disease severity and HRQL | SGRQ‡ |
| | (2) Examine the relationship between HRQL and both dyspnoea and exercise capacity | |
| | | |
6 | Douglas et al23 | Clinical trial of colchicine versus prednisone | SF-36 |
| | | |
7 | Raghu et al24 | Clinical trial of interferon-γ versus placebo | SGRQ |